Accessible text: pCPA Dashboard

Accessible text for the pCPA June 2025 Dashboard

Data effective: April 30, 2025

For questions regarding this report, please contact: [email protected]

Letters of intent

Increase access, improve consistency and reduce duplication

Since the pCPA’s inception, 671 negotiations have reached a letter of intent (LOI), including:

  • 248 for oncology
  • 73 for biosimilars
  • 76 for expensive drugs for rare diseases (EDRD)
Data for stacked line graph: Letters of intent
MonthBiosimilarEDRDOther non-oncologyOther oncology
Apr 2015053125
May 2015053625
Jun 2015053826
Jul 2015054027
Aug 2015054228
Sep 2015054428
Oct 2015054629
Nov 2015054630
Dec 2015154632
Jan 2016154932
Feb 2016155032
Mar 2016155233
Apr 2016165533
May 2016165933
Jun 2016166034
Jul 2016166135
Aug 2016166236
Sep 2016176436
Oct 2016196438
Nov 20162106539
Dec 20162106639
Jan 20173106739
Feb 20173106743
Mar 20173107443
Apr 20173107943
May 20173108043
Jun 20173118046
Jul 20174118250
Aug 20175118351
Sep 20175118354
Oct 20175118355
Nov 20176128555
Dec 20176138760
Jan 20186149163
Feb 20186159264
Mar 20186159664
Apr 20186159765
May 20186169865
Jun 20186179866
Jul 20186189967
Aug 201871910370
Sep 201872210871
Oct 201872311171
Nov 201872311371
Dec 201872611674
Jan 201972612176
Feb 201972612179
Mar 201982612780
Apr 201982612885
May 201982613086
Jun 201982613286
Jul 201982713586
Aug 201992813887
Sep 2019102814091
Oct 2019112814393
Nov 2019132814595
Dec 2019142815398
Jan 2020142815498
Feb 2020142915499
Mar 20201531155101
Apr 20201531157102
May 20201633159108
Jun 20201633159108
Jul 20201934159109
Aug 20202034162112
Sep 20202034162113
Oct 20202134162114
Nov 20202136163116
Dec 20202237164118
Jan 20212237175119
Feb 20212737177120
Mar 20212738181122
Apr 20212838181123
May 20213038181125
Jun 20213138182126
Jul 20213140183126
Aug 20213140184128
Sep 20213340188133
Oct 20213442192133
Nov 20213643193137
Dec 20213643196138
Jan 20223643198142
Feb 20223744198145
Mar 20223845199151
Apr 20224146203152
May 20224146205153
Jun 20224646205156
Jul 20224647206157
Aug 20224648206159
Sep 20224649212162
Oct 20224651214163
Nov 20224654214166
Dec 20224855216169
Jan 20234855217172
Feb 20234956220172
Mar 20234957220172
Apr 20235158222185
May 20235160226185
Jun 20235260227196
Jul 20235261229198
Aug 20235362230200
Sep 20235462232201
Oct 20235462235202
Nov 20235665236205
Dec 20235665238207
Jan 20245666241208
Feb 20245768243208
Mar 20245868244211
Apr 20245868245212
May 20245869252212
Jun 20246070256213
Jul 20246370259214
Aug 20246370260220
Sep 20246370261226
Oct 20246371263228
Nov 20246372267231
Dec 20246674267234
Jan 20256675267235
Feb 20256676267240
Mar 20256976272245
Apr 20257376276248

Savings

Lower drug costs

pCPA activities saved jurisdictions an estimated $4.87B in 2023-24.

  • $3.94B from brand name drugs
  • $935M from generic drugs
  • Since 2010, cumulative savings are estimated to be $28.8B
Data for stacked bar chart: Savings
Fiscal YearBrand name drugsGeneric drug negotiationsTotal
FY 16/17$947,007,363$355,000,000$1,302,007,363
FY 17/18$1,263,644,399$740,000,000$2,003,644,399
FY 18/19$1,539,331,475$740,000,000$2,279,331,475
FY 19/20$1,847,496,049$740,000,000$2,587,496,049
FY 20/21$2,185,315,806$740,000,000$2,925,315,806
FY 21/22$2,667,069,216$750,000,000$3,417,069,216
FY 22/23$3,142,207,211$750,000,000$3,892,207,211
FY 23/24$3,715,798,849$913,979,661$4,629,778,510
FY 24/25$3,940,000,000$935,000,000$4,875,000,000

HTA and pCPA volumes

  • There has been very high activity in the first four months of 2025, and the pCPA is projecting record volumes of health technology assessment (HTA) recommendations, negotiations engaged and negotiations closed.
Data for bar charts: HTA and PCPA volumes

Three bar charts tracking number of CDA recommendations issued, pCPA files engaged, and pCPA files closed, with the first four months of 2025 and end of year projections for 2025 shown as a stacked bar.

YearCDA recommendations issuedpCPA files engagedpCPA files closed
2016645138
2017476068
2018627364
2019636882
2020576968
2021658574
2022828390
2023618193
2024799778
202520 (+72 projected for EOY) 40 (+82 projected for EOY) 45 (+93 projected for EOY) 

pCPA activity

  • The number of files in consideration fell below 20 files for the first time in the post-COVID era.
  • The pCPA is committed to further decreasing the in-consideration timeline.
  • The number of active negotiations has significantly increased, with the pCPA negotiating more than 40 files at a time over the last 8 months.
Data for line graphs: pCPA activity 

Two line graphs:

  • Files under consideration: HTA recommendation to pCPA engagement
  • Active negotiations: pCPA engagement to LOI
MonthFiles under consideration (average)Active Negotiations (average)
Jan 202128.433
Feb 20212732.75
Mar 202125.2534.75
Apr 202126.2533.25
May 202129.233
Jun 202128.2534.75
Jul 202128.543
Aug 202129.444.2
Sep 20213439.25
Oct 202135.235.8
Nov 20212841.25
Dec 20212345.75
Jan 20222543
Feb 202228.2542.75
Mar 202231.543.5
Apr 202232.2543.5
May 202231.841.8
Jun 20223035
Jul 202229.234.8
Aug 202230.536
Sep 20223432.5
Oct 202238.230.8
Nov 202236.2534.25
Dec 20223833.75
Jan 202335.435.4
Feb 202337.2537.5
Mar 202335.7541.75
Apr 202333.435.6
May 20233033
Jun 20232733.25
Jul 20232631.4
Aug 202325.526.25
Sep 20232428.25
Oct 202323.627.8
Nov 202324.2524
Dec 202327.424
Jan 202426.7523.25
Feb 202427.521.75
Mar 202428.426.2
Apr 202429.7531.75
May 202432.529.25
Jun 202440.425.2
Jul 202439.7525
Aug 202433.527.5
Sep 202422.837.8
Oct 20241941
Nov 202418.542
Dec 202421.444.4
Jan 20252545.25
Feb 202525.2546
Mar 202518.845
Apr 20251543.75

pCPA timelines

  • All pCPA timeline metrics have improved between 2020 and 2025.
  • The typical months under consideration phase fell from 5.1 months to 2.6 months, a 49% decrease, and active negotiation timelines fell from 5.5 months to 3.2 months, a 42% decrease.
  • Between 2020 and 2024, the total timeline fell from 11 months to 8 months. Data for 2025 is not yet available.
Data for bar chart: Time under consideration*
pCPA initiation yearMedian months
to pCPA milestones
20205.06
20213.81
20224.41
20234.04
20243.32
20252.56
Data for bar chart: Active negotiation time 
pCPA initiation yearMedian months to
pCPA milestones
20205.49
20214.31
20223.49
20233.88
20243.35
20253.19
Data for bar chart:  Total time*
pCPA initiation yearMedian months to
pCPA milestones
202010.93
20219.83
20229.67
20239.17
20247.96

* Time under consideration and total timelines are only assessed for files arising from HTA recommendations, and excludes files that do not undergo negotiations. pCPA targets outlined in the brand process guidelines are approximately 2 months for file engagement, 4 months for active negotiations and 6 months combined.

Oncology drugs

  • pCPA’s negotiation times for oncology drugs have decreased over time, falling from 9 months for HTA reviews in 2020, to 6 months in 2024 (2.1 months to engagement and 3.5 months for active negotiation).
Data for bar chart: Oncology total timelines in 2024
pCPA initiation yearMedian months: HTA to pCPA completion
20209.14
20218.28
20228.98
20238.12
20245.98
Data for bar chart: Negotiation stages in 2024
StageMedian months: pCPA milestones
Time under consideration2.1
Active negotiation time3.48
Total time5.98